First PREMIER Bank boosted its stake in shares of Amgen, Inc. (NASDAQ:AMGN) by 1.3% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 9,570 shares of the medical research company’s stock after acquiring an additional 119 shares during the quarter. Amgen comprises about 1.2% of First PREMIER Bank’s investment portfolio, making the stock its 27th biggest position. First PREMIER Bank’s holdings in Amgen were worth $1,863,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other hedge funds and other institutional investors also recently modified their holdings of the business. Pure Financial Advisors Inc. increased its stake in Amgen by 8.8% during the fourth quarter. Pure Financial Advisors Inc. now owns 1,432 shares of the medical research company’s stock worth $279,000 after acquiring an additional 116 shares during the last quarter. YHB Investment Advisors Inc. increased its stake in Amgen by 9.3% during the fourth quarter. YHB Investment Advisors Inc. now owns 48,586 shares of the medical research company’s stock worth $9,458,000 after acquiring an additional 4,150 shares during the last quarter. Abner Herrman & Brock LLC increased its stake in Amgen by 4.4% during the fourth quarter. Abner Herrman & Brock LLC now owns 59,018 shares of the medical research company’s stock worth $11,489,000 after acquiring an additional 2,505 shares during the last quarter. New England Research & Management Inc. increased its stake in Amgen by 47.0% during the fourth quarter. New England Research & Management Inc. now owns 8,162 shares of the medical research company’s stock worth $1,589,000 after acquiring an additional 2,610 shares during the last quarter. Finally, Deane Retirement Strategies Inc. increased its stake in Amgen by 0.6% during the fourth quarter. Deane Retirement Strategies Inc. now owns 9,838 shares of the medical research company’s stock worth $1,915,000 after acquiring an additional 60 shares during the last quarter. 76.88% of the stock is currently owned by institutional investors.
Shares of NASDAQ AMGN traded down $3.04 during trading hours on Monday, reaching $197.52. The stock had a trading volume of 1,430,130 shares, compared to its average volume of 3,355,345. The company has a debt-to-equity ratio of 2.05, a quick ratio of 2.84 and a current ratio of 3.08. The firm has a market capitalization of $127.68 billion, a price-to-earnings ratio of 15.70, a PEG ratio of 2.05 and a beta of 1.32. Amgen, Inc. has a 52-week low of $163.31 and a 52-week high of $210.19.
Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, October 30th. The medical research company reported $3.69 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.45 by $0.24. The firm had revenue of $5.90 billion during the quarter, compared to analyst estimates of $5.78 billion. Amgen had a return on equity of 54.14% and a net margin of 9.44%. Amgen’s quarterly revenue was up 2.3% on a year-over-year basis. During the same quarter in the previous year, the business earned $3.27 earnings per share. Analysts forecast that Amgen, Inc. will post 14.24 earnings per share for the current year.
The company also recently declared a quarterly dividend, which will be paid on Friday, March 8th. Investors of record on Friday, February 15th will be issued a $1.45 dividend. This is a positive change from Amgen’s previous quarterly dividend of $1.32. The ex-dividend date of this dividend is Thursday, February 14th. This represents a $5.80 dividend on an annualized basis and a dividend yield of 2.94%. Amgen’s payout ratio is presently 41.97%.
A number of research analysts have recently commented on the company. Zacks Investment Research raised Amgen from a “hold” rating to a “buy” rating and set a $234.00 target price on the stock in a research note on Monday, October 1st. Citigroup upped their target price on Amgen from $204.00 to $210.00 and gave the company a “neutral” rating in a research note on Friday, January 4th. Mizuho reaffirmed a “buy” rating and set a $206.00 target price on shares of Amgen in a research note on Friday, October 26th. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Amgen in a research note on Thursday, October 25th. Finally, Goldman Sachs Group set a $232.00 target price on Amgen and gave the company a “buy” rating in a research note on Monday, December 10th. One equities research analyst has rated the stock with a sell rating, thirteen have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $205.50.
In other Amgen news, Director Tyler Jacks sold 20,000 shares of the company’s stock in a transaction on Thursday, December 6th. The stock was sold at an average price of $195.41, for a total transaction of $3,908,200.00. Following the completion of the sale, the director now owns 28,979 shares in the company, valued at $5,662,786.39. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, SVP Cynthia M. Patton sold 1,777 shares of the company’s stock in a transaction on Thursday, November 29th. The stock was sold at an average price of $202.88, for a total value of $360,517.76. Following the sale, the senior vice president now owns 23,090 shares of the company’s stock, valued at approximately $4,684,499.20. The disclosure for this sale can be found here. 0.27% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece was published by Zolmax and is the sole property of of Zolmax. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://zolmax.com/investing/first-premier-bank-has-1-86-million-holdings-in-amgen-inc-amgn/2824325.html.
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine.
Recommended Story: 52-Week High/Low
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.